Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease Journal Article

  


Authors: Scher, H. I.; Sternberg, C.; Heston, W. D. W.; Watson, R. C.; Niedzwiecki, D.; Smart, T.; Hollander, P.; Yagoda, A.; Community Cancer Oncology Program Investigators
Article Title: Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease
Abstract: Etoposide, a semisynthetic derivative of podophyllotoxin, was evaluated concurrently in vitro against a human derived hormone-resistant cell line, PC-3, and in vivo in bidimensionally measurable hormone-resistant human prostatic cancer. In vitro, a dose-response relationship was observed, with 74% inhibition at 10 μg/ml (1 h incubation) and >99% inhibition at 90 μg/ml, both in the range of clinically achievable concentrations. In vivo, 1 PR (5%, 95% confidence limits 0-12%) of 18+ months was observed in 20 adequately treated patients. The results confirm the limited role of etoposide in hormone-refractory disease and the need for new model systems for evaluation of potential chemotherapeutic compounds in this disease. © 1986 Springer-Verlag.
Keywords: cancer chemotherapy; clinical article; human cell; dose response; drug efficacy; adenocarcinoma; phase 2 clinical trial; etoposide; cell line; bone pain; drug resistance; prostate cancer; prostatic neoplasms; drug response; bone; drug blood level; drug therapy; adverse drug reaction; therapy; intravenous drug administration; pharmacokinetics; hormones; bone marrow depression; drug evaluation; tumor stem cell assay; male genital system; humans; human; male; priority journal; blood and hemopoietic system
Journal Title: Cancer Chemotherapy and Pharmacology
Volume: 18
Issue: 1
ISSN: 0344-5704
Publisher: Springer  
Date Published: 1986-09-01
Start Page: 24
End Page: 26
Language: English
DOI: 10.1007/bf00253058
PUBMED: 3757155
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022993627&doi=10.1007%2fBF00253058&partnerID=40&md5=b1d4767ed69ebd4e4a81717c430f230f
Notes: Article -- Export Date: 18 August 2021 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Warren Heston
    136 Heston
  2. Tracy B Smart-Curley
    70 Smart-Curley
  3. Howard Scher
    1130 Scher
  4. Donna Niedzwiecki
    61 Niedzwiecki
  5. Cora N. Sternberg
    36 Sternberg
  6. Alan Yagoda
    51 Yagoda
  7. Robin Caird Watson
    25 Caird Watson
Related MSK Work